Please login to the form below

Not currently logged in
Email:
Password:

amyotrophic lateral sclerosis

This page shows the latest amyotrophic lateral sclerosis news and features for those working in and with pharma, biotech and healthcare.

GlaxoSmithKline agrees $2.2bn dementia mAb deal with Alector

GlaxoSmithKline agrees $2.2bn dementia mAb deal with Alector

As part of the deal, GSK and Alector will develop AL001 and AL101 for a range of these disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson’s disease and Alzheimer’s ... amyotrophic lateral sclerosis (ALS) in the

Latest news

More from news
Approximately 0 fully matching, plus 50 partially matching documents found.

Latest Intelligence

  • Alzheimer’s disease: the search for a cure Alzheimer’s disease: the search for a cure

    The Dementia Consortium funds research into novel targets and treatments for dementia including Alzheimer’s disease, dementia with Lewy bodies, frontotemporal dementia, plus Parkinson’s disease, amyotrophic lateral sclerosis and

  • Perfecting the pharmaceutical pipeline with AI Perfecting the pharmaceutical pipeline with AI

    In fact, this has helped our team of scientists at BenevolentBio establish a set of hypotheses for drug candidates for Amyotrophic Lateral Sclerosis (ALS), a form of Motor Neurone Disease.  Together

  • Deal Watch July 2016 Deal Watch July 2016

    181. Cytokinetics/ Astellas. Tirasemtiv, CK-2127107 and generation skeletal muscle activators in amyotrophic lateral sclerosis.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Nobel laureate Dr Walter Gilbert joins Amylyx Pharmaceuticals Nobel laureate Dr Walter Gilbert joins Amylyx Pharmaceuticals

    The US-based pharmaceutical firm specialises in developing disease-modifying treatments for neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS).

  • Biogen Idec appoints senior neuroscientists Biogen Idec appoints senior neuroscientists

    The two will help lead Biogen Idec's research efforts across neurodegenerative and neuroimmune diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). ... He was also professor of

  • Biogen Idec names ALS unit head Biogen Idec names ALS unit head

    Donald Johns joins from Novartis. Biogen Idec has named former Novartis scientist Dr Donald Johns as head of its innovation hub for amyotrophic lateral sclerosis (ALS).

  • Andrew Gengos joins ImmunoCellular as CEO Andrew Gengos joins ImmunoCellular as CEO

    ImmunoCellular will benefit from Gengos's experience in neuroscience during his time at Neuraltus, which specialises in therapies for neurodegenerative diseases, such as amyotrophic lateral sclerosis and Parkinson's disease.

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • The ALS patient journey

    Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease (MND). ... That will be the start of ALS, but your doctor will want to rule out other things, for example, Parkinson’s disease or multiple sclerosis.

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
certain health

Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...